Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2

Arthritis Research and Therapy

Volumn 14, Issue 5, 2012, Pages

  Pircher, Joachim ^a,b   Merkle, Monika ^a   Wörnle, Markus ^a   Ribeiro, Andrea ^a   Czermak, Thomas ^b   Stampnik, Yvonn ^b   Mannell, Hanna ^b   Niemeyer, Markus ^c   Vielhauer, Volker ^a   Krötz, Florian ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Invasive Cardiology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR SUBTYPE 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR SUBTYPE 2; UNCLASSIFIED DRUG; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUPEROXIDE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLAR THROMBOSIS; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; IN VITRO STUDY; IN VIVO STUDY; MICROCIRCULATION; MOUSE; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PROTEIN AGGREGATION; REAL TIME POLYMERASE CHAIN REACTION; SKINFOLD; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; SKIN; THROMBOSIS; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; IN VITRO TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROCIRCULATION; P-SELECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SKIN; SUPEROXIDES; THROMBOMODULIN; THROMBOPLASTIN; THROMBOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867540242     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4064     Document Type: Article

References (43)

1. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756. 10.1038/nri1184, 12949498.
2. Holtmann MH, Neurath MF. Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med 2004, 4:439-444. 10.2174/1566524043360636, 15354874.
3. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501. 10.1016/S0092-8674(01)00237-9, 11239407.
4. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012, 119:651-665. 10.1182/blood-2011-04-325225, 22053109.
5. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death. Genes Dev 1998, 12:2821-2830. 10.1101/gad.12.18.2821, 9744859.
6. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118:3537-3545. 10.1172/JCI36389, 2575731, 18982160.
7. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440. 10.1146/annurev.immunol.14.1.397, 8717520.
8. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 1996, 347:1453-1458. 10.1016/S0140-6736(96)91687-6, 8676631.
9. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008, 10:202. 10.1186/ar2341, 2374473, 18226185.
10. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008, 121:S21-31. 10.1016/j.amjmed.2008.06.014, 18926166.
11. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722-732. 10.1002/art.20878, 15751097.
12. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307. 10.1161/01.CIR.0000054612.26458.B2, 12628952.
13. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999, 340:115-126. 10.1056/NEJM199901143400207, 9887164.
14. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874. 10.1038/nature01323, 12490960.
15. Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, Dellsperger KC, Zhang C. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009, 116:219-230.
16. Gao X, Belmadani S, Picchi A, Xu X, Potter BJ, Tewari-Singh N, Capobianco S, Chilian WM, Zhang C. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 2007, 115:245-254.
17. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004, 82:434-448.
18. Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003, 1:1343-1348. 10.1046/j.1538-7836.2003.00261.x, 12871267.
19. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012, 34:107-125. 10.1007/s00281-011-0282-8, 21805323.
20. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003, 23:2131-2137. 10.1161/01.ATV.0000095974.95122.EC, 14500287.
21. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005, 115:3378-3384. 10.1172/JCI27196, 1297269, 16322783.
22. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1213-1218.
23. Struthmann L, Hellwig N, Pircher J, Sohn HY, Buerkle MA, Klauss V, Mannell H, Pohl U, Krotz F. Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. J Thromb Haemost 2009, 7:1727-1735. 10.1111/j.1538-7836.2009.03582.x, 19691487.
24. Buerkle MA, Lehrer S, Sohn HY, Conzen P, Pohl U, Krotz F. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 2004, 110:2053-2059. 10.1161/01.CIR.0000143234.51796.A9, 15451781.
25. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194:927-929.
26. Mannell H, Hammitzsch A, Mettler R, Pohl U, Krotz F. Suppression of DNA-PKcs enhances FGF-2 dependent human endothelial cell proliferation via negative regulation of Akt. Cell Signal 2010, 22:88-96. 10.1016/j.cellsig.2009.09.015, 19781633.
27. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992, 99:683-690. 10.1111/1523-1747.ep12613748, 1361507.
28. Krotz F, de Wit C, Sohn HY, Zahler S, Gloe T, Pohl U, Plank C. Magnetofection--a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 2003, 7:700-710. 10.1016/S1525-0016(03)00065-0, 12718913.
29. Wornle M, Schmid H, Banas B, Merkle M, Henger A, Roeder M, Blattner S, Bock E, Kretzler M, Grone HJ, Schlondorff D. Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 2006, 168:370-385. 10.2353/ajpath.2006.050491, 1606499, 16436653.
30. Mannell HK, Pircher J, Chaudhry DI, Alig SK, Koch EG, Mettler R, Pohl U, Krotz F. ARNO regulates VEGF-dependent tissue responses by stabilizing endothelial VEGFR-2 surface expression. Cardiovasc Res 2012, 93:111-119. 10.1093/cvr/cvr265, 22002459.
31. Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, Krombach F, Messmer K. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998, 92:507-515.
32. Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, Ferrero ME, Corti A. Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am J Physiol Cell Physiol 2001, 281:C1173-1179.
33. Pignatelli P, De Biase L, Lenti L, Tocci G, Brunelli A, Cangemi R, Riondino S, Grego S, Volpe M, Violi F. Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood 2005, 106:1992-1994. 10.1182/blood-2005-03-1247, 15956282.
34. Piguet PF, Vesin C, Da Kan C. Activation of platelet caspases by TNF and its consequences for kinetics. Cytokine 2002, 18:222-230. 10.1006/cyto.2002.0889, 12126645.
35. Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-alpha. J Clin Invest 2003, 112:1589-1596. 259133, 14617760.
36. Yoshida H, Yilmaz CE, Granger DN. Role of tumor necrosis factor-alpha in the extraintestinal thrombosis associated with colonic inflammation. Inflamm Bowel Dis 2011, 17:2217-2223. 10.1002/ibd.21593, 3123669, 21987296.
37. Kollias G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002, 13:315-321. 10.1016/S1359-6101(02)00019-9, 12220546.
38. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003, 10:45-65. 10.1038/sj.cdd.4401189, 12655295.
39. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004, 24:2137-2142. 10.1161/01.ATV.0000143933.20616.1b, 15345516.
40. Chandrasekharan UM, Mavrakis L, Bonfield TL, Smith JD, DiCorleto PE. Decreased atherosclerosis in mice deficient in tumor necrosis factor-alpha receptor-II (p75). Arterioscler Thromb Vasc Biol 2007, 27:e16-17. 10.1161/01.ATV.0000255551.33365.22, 17301316.
41. Blessing E, Bea F, Kuo CC, Campbell LA, Chesebro B, Rosenfeld ME. Lesion progression and plaque composition are not altered in older apoE-/- mice lacking tumor necrosis factor-alpha receptor p55. Atherosclerosis 2004, 176:227-232. 10.1016/j.atherosclerosis.2004.05.033, 15380444.
42. Chandrasekharan UM, Siemionow M, Unsal M, Yang L, Poptic E, Bohn J, Ozer K, Zhou Z, Howe PH, Penn M, DiCorleto PE. Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-induced leukocyte-endothelial interaction in vivo. Blood 2007, 109:1938-1944. 10.1182/blood-2006-05-020875, 1801063, 17068152.
43. Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:1831-1834. 10.1136/ard.2011.153536, 3168333, 21784722.